Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

References

• Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):1–9. doi:10.1016/j.anai.2020.12.020.
   PubMed Web of Science ®Google Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi:10.1016/S0140-6736(20)31286-1.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347. doi:10.1016/j.anai.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548–552.e3. doi:10.1016/j.anai.2017.09.076.
   PubMed Web of Science ®Google Scholar
• Ricci G, Bellini F, Dondi A, et al. Atopic dermatitis in adolescence. Dermatol Reports. 2012;4(1):e1. doi:10.4081/dr.2012.e1.
   PubMedGoogle Scholar
• Halvorsen JA, Lien L, Dalgard F, et al. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. J Invest Dermatol. 2014;134(7):1847–1854. doi:10.1038/jid.2014.70.
   PubMed Web of Science ®Google Scholar
• Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668–671. doi:10.1016/j.jaci.2011.05.003.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476–486. doi:10.1111/pai.12095.
   PubMed Web of Science ®Google Scholar
• Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022;12(12):2653–2668. doi:10.1007/s13555-022-00819-6.
   PubMed Web of Science ®Google Scholar
• Brenninkmeijer EEA, Legierse CM, Sillevis Smitt JH, et al. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol. 2009;26(1):14–22. doi:10.1111/j.1525-1470.2008.00745.x.
   PubMed Web of Science ®Google Scholar
• Saunes M, Smidesang I, Holmen TL, et al. Atopic dermatitis in adolescent boys is associated with greater psychological morbidity compared with girls of the same age: the young‐HUNT study. Br J Dermatol. 2007;156(2):283–288. doi:10.1111/j.1365-2133.2006.07688.x.
   PubMed Web of Science ®Google Scholar
• Oh SH, Bae BG, Park CO, et al. Association of stress with symptoms of atopic dermatitis. Acta Derm Venereol. 2010;90(6):582–588. doi:10.2340/00015555-0933.
   PubMed Web of Science ®Google Scholar
• Sanclemente G, Hernandez N, Chaparro D, et al. Epidemiologic features and burden of atopic dermatitis in adolescent and adult patients: a cross-sectional multicenter study. World Allergy Organ J. 2021;14(12):100611. doi:10.1016/j.waojou.2021.100611.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. doi:10.1001/jamadermatol.2019.3336.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Ruxolitinib cream 1.5%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2023;24(1):143–151. doi:10.1007/s40257-022-00748-2.
   PubMed Web of Science ®Google Scholar
• Sideris N, Paschou E, Bakirtzi K, et al. New and upcoming topical treatments for atopic dermatitis: a review of the literature. J Clin Med. 2022;11(17):4974. doi:10.3390/jcm11174974.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. doi:10.1111/bjd.19574.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404–413. doi:10.1001/jamadermatol.2022.0029.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873. doi:10.1001/jamadermatol.2020.1406.
   PubMed Web of Science ®Google Scholar
• Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783–798. doi:10.1007/s40257-020-00548-6.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE Mono-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266. doi:10.1016/S0140-6736(20)30732-7.
   PubMed Web of Science ®Google Scholar
• Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15(9):2129–2139. doi:10.1080/21645515.2019.1582403.
   PubMed Web of Science ®Google Scholar
• Stölzl D, Weidinger S, Drerup K. A new era has begun: treatment of atopic dermatitis with biologics. Allergol Select. 2021;5(01):265–273. doi:10.5414/ALX02259E.
   PubMedGoogle Scholar
• Bieber T. Interleukin‐13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954.
   PubMed Web of Science ®Google Scholar
• Okragly A, Ryuzoji A, Daniels M, et al. Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab. 4th inflammatory skin disease summit, New York. Exp Dermatol. 2021;30(Suppl. 2):3–43. November 2–6, 2021. doi:10.1111/exd.14457.
   PubMedGoogle Scholar
• Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–1091. doi:10.1056/NEJMoa2206714.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182–191. doi:10.1001/jamadermatol.2022.5534.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D. A treatise on topical corticosteroids in dermatology. Use, misuse and abuse. Indian J Dermatol Venereol Leprol. 2018;84:761–762. doi:10.4103/ijdvl.IJDVL_755_18.
   Google Scholar
• Ghamrawi R, Bell KA, Balogh EA, et al. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert Opin Biol Ther. 2020;20(12):1435–1445. doi:10.1080/14712598.2021.1840548.
   PubMed Web of Science ®Google Scholar
• Patel N, Feldman SR. Adherence in atopic dermatitis. Adv Exp Med Biol. 2017;1027:139–159. doi:10.1007/978-3-319-64804-0_12.
   PubMed Web of Science ®Google Scholar
• Kelly KA, Ewulu A, Emmerich VK, et al. Refractory pediatric psoriasis and atopic dermatitis: the importance of ­therapeutical adherence and biological management. Biomedicines. 2021;9(8):958. doi:10.3390/biomedicines9080958.
   PubMed Web of Science ®Google Scholar
• Freitas E, Guttman-Yassky E, Torres T. Tralokinumab for the treatment of atopic dermatitis. Am J Clin Dermatol. 2021;22(5):625–638. doi:10.1007/s40257-021-00613-8.
   PubMed Web of Science ®Google Scholar
• Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56(2):211–216. doi:10.1016/j.jaad.2006.05.073.
   PubMed Web of Science ®Google Scholar